Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER

BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties. METHODS: Patient data from three randomised, double-blind, placebo-controlled, phase III studies ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshua, Anthony M., Armstrong, Andrew, Crumbaker, Megan, Scher, Howard I., de Bono, Johann, Tombal, Bertrand, Hussain, Maha, Sternberg, Cora N., Gillessen, Silke, Carles, Joan, Fizazi, Karim, Lin, Ping, Duggan, William, Sugg, Jennifer, Russell, David, Beer, Tomasz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394474/
https://www.ncbi.nlm.nih.gov/pubmed/35643841
http://dx.doi.org/10.1016/j.ejca.2022.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394474/
https://www.ncbi.nlm.nih.gov/pubmed/35643841
http://dx.doi.org/10.1016/j.ejca.2022.04.005

Ejemplares similares